Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes

Activation of protein kinase C (PKC) is implicated as an important mechanism by which diabetes causes vascular complications. We have recently shown that a PKC β inhibitor ameliorates not only early diabetes‐induced glomerular dysfunction such as glomerular hyperfiltration and albuminuria, but also overexpression of glomerular mRNA for transforming growth factor β1 (TGF‐βΙ) and extracellular matrix (ECM) proteins in streptozoto‐cin‐induced diabetic rats, a model for type 1 diabetes. In this study, we examined the long‐term effects of a PKC β inhibitor on glomerular histology as well as on biochemical and functional abnormalities in glomeruli of db/db mice, a model for type 2 diabetes. Administration of a PKC β inhibitor reduced urinary albumin excretion rates and inhibited glo‐merular PKC activation in diabetic db/db mice. Administration of a PKC β inhibitor also prevented the mesangial expansion observed in diabetic db/db mice, possibly through attenuation of glomerular expression of TGF‐β and ECM proteins such as fibronectin and type IV collagen. These findings provide the first in vivo evidence that the long‐term inhibition of PKC activation in the renal glomeruli can ameliorate glomerular pathologies in diabetic state, and thus suggest that a PKC β inhibitor might be an useful therapeutic strategy for the treatment of diabetic nephropathy.—Koya, D., Haneda, M., Nakagawa, H., Isshiki, K., Sato, H., Maeda, S., Sugimoto, T., Yasuda, H., Kashiwagi, A., Ways, D. K., King, G. L., Kikkawa, R. Amelioration of accelerated diabetic mesangial expansion by treatment with A PKC b inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14, 439–447 (2000)

[1]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[2]  C. Whiteside,et al.  Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. , 1998, Diabetes.

[3]  M. Haneda,et al.  Evidence for Existence of Polyol Pathway in Cultured Rat Mesangial Cells , 1987, Diabetes.

[4]  D. Noonan,et al.  Altered Steady-State mRNA Levels of Basement Membrane Proteins in Diabetic Mouse Kidneys and Thromboxane Synthase Inhibition , 1990, Diabetes.

[5]  G. King,et al.  Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. , 1997, The Journal of clinical investigation.

[6]  K. Sharma,et al.  Hyperglycemia and Diabetic Kidney Disease: The Case for Transforming Growth Factor–β as a Key Mediator , 1995, Diabetes.

[7]  M. Haneda,et al.  Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. , 1990, Metabolism: clinical and experimental.

[8]  Y. Tomino,et al.  ECM Gene Expression and Its Modulation by Insulin in Diabetic Rats , 1992, Diabetes.

[9]  S. Lee,et al.  Early immunopathologic events in experimental diabetic nephropathy: a study in db/db mice. , 1980, Experimental and molecular pathology.

[10]  S. J. Elliott,et al.  The contribution of increased collagen synthesis to human glomerulosclerosis: a quantitative analysis of alpha 2IV collagen mRNA expression by competitive polymerase chain reaction , 1992, The Journal of experimental medicine.

[11]  M. Steffes,et al.  Glomerular filtration surface in type I diabetes mellitus. , 1986, Kidney international.

[12]  K. Sharma,et al.  Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. , 1994, The American journal of physiology.

[13]  W. Border,et al.  Transforming growth factor beta in tissue fibrosis. , 1994, The New England journal of medicine.

[14]  D. Sutherland,et al.  Reversal of lesions of diabetic nephropathy after pancreas transplantation. , 1999, The New England journal of medicine.

[15]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[16]  S. Bursell,et al.  Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.

[17]  C. Davidson,et al.  Increase in Diacylglycerol Mass in Isolated Glomeruli by Glucose From De Novo Synthesis of Glycerolipids , 1990, Diabetes.

[18]  M. Sporn,et al.  Activation of the second promoter of the transforming growth factor-beta 1 gene by transforming growth factor-beta 1 and phorbol ester occurs through the same target sequences. , 1989, The Journal of biological chemistry.

[19]  R. Butkowski,et al.  Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry. , 1994, Kidney international.

[20]  S. Adler,et al.  Early increased renal procollagen alpha 1(IV) mRNA levels in streptozotocin induced diabetes. , 1992, Kidney international.

[21]  M. Sporn,et al.  Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-ras oncogene , 1991, Molecular and cellular biology.

[22]  F. DeRubertis,et al.  Activation of Protein Kinase C in Glomerular Cells in Diabetes: Mechanisms and Potential Links to the Pathogenesis of Diabetic Glomerulopathy , 1994, Diabetes.

[23]  W. Border,et al.  Transforming Growth Factor β in Tissue Fibrosis , 1994 .

[24]  N. Nakao,et al.  Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. , 1998, The American journal of pathology.

[25]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[26]  A. Kornblihtt,et al.  Interaction of the -170 cyclic AMP response element with the adjacent CCAAT box in the human fibronectin gene promoter. , 1992, The Journal of biological chemistry.

[27]  Jia Guo,et al.  The Renal TGF-β System in the db/db Mouse Model of Diabetic Nephropathy , 1998, Nephron Experimental Nephrology.

[28]  F N Ziyadeh,et al.  Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. , 1995, The Journal of clinical investigation.

[29]  C. Alpers,et al.  Cellular events in the evolution of experimental diabetic nephropathy. , 1995, Kidney international.

[30]  B. Chavers,et al.  Mesangial Expansion as a Central Mechanism for Loss of Kidney Function in Diabetic Patients , 1989, Diabetes.

[31]  C. Godson,et al.  Protein kinases C: potential targets for intervention in diabetic nephropathy , 1998, Current opinion in nephrology and hypertension.

[32]  L. Melton,et al.  Epidemiology of Persistent Proteinuria in Type II Diabetes Mellitus: Population-Based Study in Rochester, Minnesota , 1988, Diabetes.

[33]  A. Michael,et al.  Polyantigenic Expansion of Basement Membrane Constituents in Diabetic Nephropathy , 1983, Diabetes.

[34]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[35]  Masakazu Haneda,et al.  Mitogen-Activated Protein Kinase Cascade Is Activated in Glomeruli of Diabetic Rats and Glomerular Mesangial Cells Cultured Under High Glucose Conditions , 1997, Diabetes.

[36]  E Ruoslahti,et al.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Greene,et al.  Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. , 1987, The New England journal of medicine.

[38]  F. DeRubertis,et al.  Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. , 1989, The Journal of clinical investigation.

[39]  I. Verma,et al.  Cross-talk in signal transduction: TPA-inducible factor jun/AP-1 activates cAMP-responsive enhancer elements. , 1990, Oncogene.

[40]  M. Steffes,et al.  Glomerular Structure in Nonproteinuric IDDM Patients With Various Levels of Albuminuria , 1994, Diabetes.

[41]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[42]  T. Miyata,et al.  Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. , 1999, Journal of the American Society of Nephrology : JASN.

[43]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[44]  K. Sharma,et al.  Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: possible mediation via protein kinase C. , 1995, Biochemical and biophysical research communications.

[45]  S. Adler,et al.  Early increased renal procollagen α1(IV) mRNA levels in streptozotocin induced diabetes , 1992 .

[46]  H. Parving,et al.  Unchanged Incidence of Diabetic Nephropathy in IDDM Patients , 1995, Diabetes.

[47]  S. Adler Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. , 1994, Journal of the American Society of Nephrology : JASN.

[48]  K. Sharma,et al.  The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. , 1998, Experimental nephrology.

[49]  W. Couser,et al.  The cytoskeletal linking proteins, moesin and radixin, are upregulated by platelet-derived growth factor, but not basic fibroblast growth factor in experimental mesangial proliferative glomerulonephritis. , 1996, The Journal of clinical investigation.

[50]  D. Troyer,et al.  High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. , 1991, The American journal of physiology.

[51]  J. Kreisberg,et al.  High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. , 1994, Kidney international.

[52]  Serum stimulation of fibronectin gene expression appears to result from rapid serum-induced binding of nuclear proteins to a cAMP response element. , 1990, The Journal of biological chemistry.

[53]  G. King,et al.  Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. , 1997, Journal of the American Society of Nephrology : JASN.

[54]  C. Alpers,et al.  Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. , 1991, Kidney international.

[55]  M. Steffes,et al.  Structural-functional relationships in diabetic nephropathy. , 1984, The Journal of clinical investigation.

[56]  J. Wetzels,et al.  The changing natural history of nephropathy in type I diabetes. , 1986, The American journal of medicine.

[57]  P. Bennett,et al.  Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians. , 1989, Kidney international.

[58]  K. Sharma,et al.  Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. , 1994, The Journal of clinical investigation.

[59]  G. King,et al.  Protein kinase C activation and the development of diabetic complications. , 1998, Diabetes.

[60]  L. Aiello,et al.  Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. , 1996, The Journal of clinical investigation.